Actively Recruiting
Study of LY4268989 with Mirikizumab Compared to Mirikizumab Alone in Adults with Moderately to Severely Active Ulcerative Colitis
Led by Eli Lilly and Company · Updated on 2026-11-04
252
Participants Needed
147
Research Sites
95 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of LY4268989 combined with mirikizumab compared to mirikizumab alone in adults with moderately to severely active ulcerative colitis UC. This Phase 2, randomized, double-blind study focuses on treatment for UC, aiming to determine whether the combination improves clinical remission and response rates. Participants will receive either LY4268989 orally along with mirikizumab administered first intravenously then subcutaneously, or mirikizumab with a placebo oral treatment. Responders during the study will be re-randomized for a second study period. Treatment lasts approximately 104 weeks with up to 21 visits. Throughout the study, participants will attend regular visits for assessments including clinical remission status using the modified Mayo Score at weeks 12, 24, and 48, as well as endoscopic improvement and symptomatic remission. Safety and response to treatment will be monitored over about 118 weeks of total participation.
CONDITIONS
Brief Title
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here